Latest Whitepapers

Currently, various treatments are available to cancer patients, such as chemotherapy, targeted therapy and immunotherapy. Targeted therapy is a type of precision medicine that targets the proteins that control the growth, division and spread of cancer cells.

Biobanks and biorepositories play a crucial role in medical research by offering robust, readily available and even rare biospecimen samples for clinical, biomedical and research studies.

Since the first cases of COVID-19 were identified in December 2019, the disease has spread across the world, claiming over half a million lives and affecting millions of others.

Fast, high-throughput viral genome sequencing for the identification and detection of pathogens has become an invaluable tool in variant detection and monitoring.

Immuno-oncology research investigates how the immune system interacts with cancer cells within the tumor microenvironment, a process which is not fully understood.

The successful use of immunotherapies to help combat cancer has expanded rapidly in the last few years, with many therapies now approved for clinical use.

Download this whitepaper to discover how to overcome the limitations of PCR testing, how RT-qPCR will impact diagnostics both in lab and at point of care and how RT-qPCR is driving new methods and applications.

As we have gained a greater understanding of cancer biology, therapeutic interventions have evolved from a one-size-fits-all approach to more targeted approaches, which afford patients not only longer lives but increased quality of life.

The quality of indoor air dramatically affects the health of animals and humans during livestock production. Airborne transmission has been suspected of being responsible for epidemics of highly infectious diseases in livestock production, and due to the COVID-19 pandemic, there has been increasing concern about the role of wild animals in the epidemiology of most zoonoses.

Cell-based chimeric antigen receptor (CAR) T-cell therapies have rapidly advanced from preclinical research. This success has driven an influx of companies to further develop CAR T-cell constructs to make them more effective, safe and persistent.